Background: This study evaluated the prognostic impact of Trop-2, CD47, and CD163 expression on clinical outcomes in triple-negative breast cancer (TNBC) and investigated their interactions with tumor progression. The gene discussed is TACSTD2; the disease is triple-negative breast carcinoma.